Twist Bioscience (TWST) reported $377M in revenue for fiscal 2025, +20.3% year on year. That ranks #2381 by revenue among 2853 SEC filers and #234 in Healthcare. It posted a net loss of −$77.7M for the same year. Revenue has grown 55.9% a year on average since 2017 ($10.8M then). The fiscal 2025 balance sheet shows $638M in total assets, $149M in cash and $625,000 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerIncludingAssessedTax | $377M | +20.3% | FY20252025-09-30 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$136M | +$84.6M | FY20252025-09-30 |
| Net incomeNetIncomeLoss | −$77.7M | +$131M | FY20252025-09-30 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$47.6M | +$16.5M | FY20252025-09-30 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $28.0M | +451.7% | FY20252025-09-30 |
| Total assetsAssets | $638M | +4.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $456M | +0.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $149M | −32.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $625,000 | −83.0% | FY20202020-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $111M | −$44.0M | Open → |
| Q2 20262026-06-30 | $118M | −$35.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Twist Bioscience Corp
- Ticker
- TWST
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 09-30
- CIK
- 0001581280
Filings
- 10-QAug 3, 2026Open filing →
- 10-QMay 4, 2026Open filing →
- 10-QFeb 2, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Sinovac BiotechSVA | $386M | −$199M |
| Sonida Senior LivingSNDA | $381M | −$72.5M |
| CaredxCDNA | $380M | −$21.4M |
| Twist BioscienceTWST | $377M | −$77.7M |
| Pharming GroupPHAR | $376M | $2.9M |
| Arcutis BiotherapeuticsARQT | $376M | −$16.1M |
| InmodeINMD | $370M | $93.8M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Twist Bioscience — Key figures |url=https://companiesranked.com/en/company/twist-bioscience |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Twist Bioscience — Key figures. CompaniesRanked. https://companiesranked.com/en/company/twist-bioscienceBibTeX
@misc{companiesranked-en-company-twist-bioscience-2026,
author = {{CompaniesRanked}},
title = {{Twist Bioscience — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/twist-bioscience}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.